SELLAS Life Sciences Group (SLS) Competitors $1.74 +0.12 (+7.41%) Closing price 04:00 PM EasternExtended Trading$1.72 -0.02 (-1.15%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLS vs. RLAY, STOK, SAGE, MRVI, MGTX, URGN, TRML, MNMD, DNA, and SIGAShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Relay Therapeutics (RLAY), Stoke Therapeutics (STOK), Sage Therapeutics (SAGE), Maravai LifeSciences (MRVI), MeiraGTx (MGTX), UroGen Pharma (URGN), Tourmaline Bio (TRML), Mind Medicine (MindMed) (MNMD), Ginkgo Bioworks (DNA), and SIGA Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. Relay Therapeutics Stoke Therapeutics Sage Therapeutics Maravai LifeSciences MeiraGTx UroGen Pharma Tourmaline Bio Mind Medicine (MindMed) Ginkgo Bioworks SIGA Technologies Relay Therapeutics (NASDAQ:RLAY) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts recommend RLAY or SLS? Relay Therapeutics currently has a consensus price target of $18.36, suggesting a potential upside of 460.72%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Relay Therapeutics is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, RLAY or SLS? SELLAS Life Sciences Group has lower revenue, but higher earnings than Relay Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$10.01M55.48-$341.97M-$2.39-1.37SELLAS Life Sciences Group$1M155.53-$37.34M-$0.52-3.16 Does the media favor RLAY or SLS? In the previous week, Relay Therapeutics had 7 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 10 mentions for Relay Therapeutics and 3 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.92 beat Relay Therapeutics' score of 0.48 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SELLAS Life Sciences Group 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RLAY or SLS? Relay Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Does the MarketBeat Community prefer RLAY or SLS? Relay Therapeutics received 52 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 69.66% of users gave Relay Therapeutics an outperform vote while only 55.56% of users gave SELLAS Life Sciences Group an outperform vote. CompanyUnderperformOutperformRelay TherapeuticsOutperform Votes6269.66% Underperform Votes2730.34% SELLAS Life Sciences GroupOutperform Votes1055.56% Underperform Votes844.44% Is RLAY or SLS more profitable? Relay Therapeutics' return on equity of -45.75% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -45.75% -40.75% SELLAS Life Sciences Group N/A -629.46%-178.65% Do insiders and institutionals hold more shares of RLAY or SLS? 97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by insiders. Comparatively, 1.2% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryRelay Therapeutics beats SELLAS Life Sciences Group on 12 of the 17 factors compared between the two stocks. Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.63M$6.82B$5.54B$7.99BDividend YieldN/A2.96%5.09%4.22%P/E Ratio-2.397.4322.6818.71Price / Sales155.53253.33405.96105.45Price / CashN/A65.8538.1834.62Price / Book-6.586.606.844.31Net Income-$37.34M$143.41M$3.22B$248.10M7 Day Performance17.50%3.17%1.84%2.02%1 Month Performance50.92%5.52%3.19%3.60%1 Year Performance21.85%-2.82%16.30%5.11% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group0.8008 of 5 stars$1.74+7.4%N/A+26.6%$164.51M$1M-2.5210Gap UpHigh Trading VolumeRLAYRelay Therapeutics2.0014 of 5 stars$2.75+2.2%$18.36+567.8%-50.6%$466.19M$10.01M-1.05330News CoveragePositive NewsGap DownSTOKStoke Therapeutics3.3893 of 5 stars$8.61+12.0%$24.67+186.5%-14.6%$465.61M$36.56M-4.10100Upcoming EarningsHigh Trading VolumeSAGESage Therapeutics3.8701 of 5 stars$7.44+0.1%$8.81+18.4%-43.7%$457.42M$41.24M-1.13690Earnings ReportAnalyst RevisionNews CoverageMRVIMaravai LifeSciences4.0457 of 5 stars$1.77flat$6.34+258.4%-75.9%$450.18M$259.19M-1.08610Upcoming EarningsOptions VolumeMGTXMeiraGTx4.5024 of 5 stars$5.65+4.4%$24.50+333.6%+45.5%$445.53M$33.28M-4.67300Upcoming EarningsShort Interest ↑News CoverageURGNUroGen Pharma4.3015 of 5 stars$9.66-0.1%$32.86+240.1%-20.8%$445.27M$90.40M-3.07200Analyst ForecastAnalyst RevisionNews CoverageTRMLTourmaline Bio2.7352 of 5 stars$16.76+4.7%$45.20+169.7%+13.6%$430.48MN/A-5.9444Earnings ReportNews CoveragePositive NewsMNMDMind Medicine (MindMed)2.3594 of 5 stars$5.66-1.9%$25.11+343.7%-30.1%$426.58MN/A-2.5040Upcoming EarningsNews CoveragePositive NewsGap UpDNAGinkgo Bioworks0.6777 of 5 stars$7.35-6.4%$4.58-37.8%N/A$426.55M$227.04M-0.56640Upcoming EarningsNews CoverageGap UpSIGASIGA Technologies1.8155 of 5 stars$5.97-0.3%N/A-41.7%$426.48M$138.72M4.9840Upcoming EarningsEx-DividendOptions VolumeNews CoveragePositive News Related Companies and Tools Related Companies Relay Therapeutics Alternatives Stoke Therapeutics Alternatives Sage Therapeutics Alternatives Maravai LifeSciences Alternatives MeiraGTx Alternatives UroGen Pharma Alternatives Tourmaline Bio Alternatives Mind Medicine (MindMed) Alternatives Ginkgo Bioworks Alternatives SIGA Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLS Stock Free SLS Stock Alerts